Insider · CIK 0001733369
Vimal Mehta
Files at BTAIQ (BioXcel Therapeutics, Inc.). First filing Dec 17, 2024, latest May 22, 2026.
In brief
Vimal Mehta files SEC Form 4 as CEO, president, director and 10% owner at BTAIQ (BioXcel Therapeutics, Inc.). Since Dec 17, 2024, Vimal Mehta has reported 0 open-market buys worth $0 and 2 open-market sells worth $22k, the latest filed on May 22, 2026.
A track record needs three past buys with six months of prices behind them; Vimal Mehta has 0, so none is measured yet.
The newest scored trade: sold $21k of BTAIQ on May 20, 2026, filed May 22, 2026, scored 10 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $21k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
BTAIQ: BioXcel Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 10Weak | BioXcel Therapeutics, Inc. | $21k 19,419 shares | -22% | - | |
| 5Weak | BioXcel Therapeutics, Inc. | $1,131 3,117 shares | -5% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 20, 2026 | BTAIQ BioXcel Therapeutics, Inc. | 19,419 0.06% of outstanding | $21k | May 20, 2026 | none |
| Dec 16, 2024 | BTAIQ BioXcel Therapeutics, Inc. | 983 0.00% of outstanding | $340 | Dec 16, 2024 | $1,367 |
Transactions
Every row this insider has filed, 40 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +219 | - | - | 69,817 | Jun 17, 2026 |
| Jun 15, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -219 | $0.00 | $0 | 1,313 | Jun 17, 2026 |
| May 4, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +49,758 | - | - | 89,017 | May 22, 2026 |
| May 20, 2026 | BTAIQ BioXcel Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -19,419 | $1.09 | $21k | 69,598 | May 22, 2026 |
| May 4, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative10b5-1 | -49,758 | $0.00 | $0 | 149,274 | May 22, 2026 |
| May 1, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +18,000 | - | - | 39,259 | May 7, 2026 |
| May 1, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -18,000 | $0.00 | $0 | 0 | May 7, 2026 |
| Mar 14, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +164 | - | - | 21,040 | Mar 16, 2026 |
| Mar 15, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +219 | - | - | 21,259 | Mar 16, 2026 |
| Mar 14, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -164 | $0.00 | $0 | 488 | Mar 16, 2026 |
| Mar 15, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -219 | $0.00 | $0 | 1,532 | Mar 16, 2026 |
| Jan 1, 2026 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +199,032 | $0.00 | $0 | 200,783 | Jan 5, 2026 |
| Dec 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +164 | - | - | 20,657 | Dec 15, 2025 |
| Dec 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +219 | - | - | 20,876 | Dec 15, 2025 |
| Dec 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -164 | $0.00 | $0 | 652 | Dec 15, 2025 |
| Dec 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -219 | $0.00 | $0 | 1,751 | Dec 15, 2025 |
| Sep 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +163 | - | - | 20,274 | Sep 16, 2025 |
| Sep 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +219 | - | - | 20,493 | Sep 16, 2025 |
| Sep 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -163 | $0.00 | $0 | 816 | Sep 16, 2025 |
| Sep 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -219 | $0.00 | $0 | 1,970 | Sep 16, 2025 |
| Aug 1, 2025 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +18,000 | $0.00 | $0 | 18,000 | Aug 5, 2025 |
| Jul 22, 2025 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Common Stock | +15,625 | - | - | 20,111 | Jul 22, 2025 |
| Jun 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +163 | - | - | 4,267 | Jun 16, 2025 |
| Jun 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +219 | - | - | 4,486 | Jun 16, 2025 |
| Jun 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -163 | $0.00 | $0 | 979 | Jun 16, 2025 |
| Jun 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -219 | $0.00 | $0 | 2,189 | Jun 16, 2025 |
| Jul 22, 2024 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +6,250 | $0.00 | $0 | 6,250 | Apr 1, 2025 |
| Mar 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +162 | - | - | 3,887 | Mar 17, 2025 |
| Mar 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +217 | - | - | 4,104 | Mar 17, 2025 |
| Mar 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -162 | $0.00 | $0 | 1,142 | Mar 17, 2025 |
| Mar 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -217 | $0.00 | $0 | 2,408 | Mar 17, 2025 |
| Jan 7, 2025 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +660,000 | $0.00 | $0 | 660,000 | Jan 10, 2025 |
| Dec 14, 2024 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +2,610 | - | - | 58,403 | Dec 17, 2024 |
| Dec 15, 2024 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +3,500 | - | - | 61,903 | Dec 17, 2024 |
| Dec 16, 2024 | BTAIQ BioXcel Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -983 | $0.36 | $358 | 60,920 | Dec 17, 2024 |
| Dec 16, 2024 | BTAIQ BioXcel Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,134 | $0.36 | $773 | 59,605 | Dec 17, 2024 |
| Dec 14, 2024 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative10b5-1 | -2,610 | $0.00 | $0 | 13,049 | Dec 17, 2024 |
| Dec 15, 2024 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative10b5-1 | -3,500 | $0.00 | $0 | 31,500 | Dec 17, 2024 |
| Dec 14, 2023 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +2,609 | - | - | 32,222 | Dec 18, 2023 |
| Dec 14, 2023 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -2,609 | $0.00 | $0 | 23,485 | Dec 18, 2023 |
Questions about Vimal Mehta
Answered from the filings on this page, as of the latest one.
Is Vimal Mehta buying or selling?
In the last 12 months Vimal Mehta reported 0 open-market buys worth $0 and 1 open-market sell worth $21k on SEC Form 4; the latest was sold $21k of BTAIQ on May 20, 2026. Grants, option exercises and tax withholding are not counted.
How did Vimal Mehta's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Vimal Mehta has 0.
Where does Vimal Mehta file Form 4?
Vimal Mehta has filed Form 4 at BTAIQ (BioXcel Therapeutics, Inc.) as CEO and President. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.